Lipocine (NASDAQ:LPCN) Releases Earnings Results, Beats Expectations By $0.08 EPS

Lipocine (NASDAQ:LPCN) posted its quarterly earnings data on Tuesday. The specialty pharmaceutical company reported ($0.32) earnings per share for the quarter, topping the consensus estimate of ($0.40) by $0.08, FiscalAI reports. Lipocine had a negative net margin of 571.18% and a negative return on equity of 66.70%. The firm had revenue of $0.19 million during the quarter, compared to analysts’ expectations of $0.21 million.

Lipocine Stock Up 1.7%

NASDAQ LPCN traded up $0.04 on Tuesday, reaching $2.15. The company had a trading volume of 17,760 shares, compared to its average volume of 228,463. The stock’s 50 day moving average is $2.28 and its 200-day moving average is $4.87. The stock has a market cap of $17.68 million, a price-to-earnings ratio of -1.14 and a beta of 0.44. Lipocine has a 52 week low of $1.81 and a 52 week high of $12.37.

Hedge Funds Weigh In On Lipocine

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Citadel Advisors LLC bought a new stake in shares of Lipocine in the 3rd quarter valued at about $41,000. Jane Street Group LLC bought a new stake in Lipocine in the fourth quarter valued at approximately $85,000. Renaissance Technologies LLC raised its holdings in Lipocine by 3.6% in the fourth quarter. Renaissance Technologies LLC now owns 37,397 shares of the specialty pharmaceutical company’s stock worth $300,000 after purchasing an additional 1,300 shares during the period. Boothbay Fund Management LLC bought a new position in shares of Lipocine during the fourth quarter worth $441,000. Finally, Geode Capital Management LLC grew its holdings in shares of Lipocine by 2.2% in the 4th quarter. Geode Capital Management LLC now owns 62,450 shares of the specialty pharmaceutical company’s stock valued at $502,000 after buying an additional 1,374 shares during the period. Institutional investors own 9.11% of the company’s stock.

Wall Street Analyst Weigh In

Several equities research analysts have recently commented on the company. Weiss Ratings cut Lipocine from a “sell (d-)” rating to a “sell (e+)” rating in a research note on Thursday, June 18th. HC Wainwright reiterated a “neutral” rating on shares of Lipocine in a report on Monday, April 6th. Finally, Wall Street Zen raised Lipocine from a “sell” rating to a “hold” rating in a report on Saturday, July 18th. One research analyst has rated the stock with a Strong Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat, the stock has an average rating of “Hold” and a consensus price target of $15.00.

Lipocine Company Profile

Lipocine Inc is a clinical-stage pharmaceutical company focused on the development and commercialization of oral drug delivery technologies. The company’s core expertise lies in lipid-based formulations designed to improve the bioavailability of therapeutics that traditionally require injectable administration. By leveraging proprietary technologies, Lipocine aims to offer patient-friendly alternatives with the potential for more consistent pharmacokinetic profiles and improved compliance.

The company’s lead product, TLANDO (LPCN 1021), is an oral testosterone replacement therapy approved by the U.S.